NANJING, Jiangsu, China, June 7 A new study showsthat umbilical cord mesenchymal stem cell transplant (UC-MSCT) may improvesymptoms and biochemical values in patients with severe refractory systemiclupus erythematosus (SLE).
In research published online (ahead of print) May 6, 2010 in Arthritis &Rheumatism, lead author and Director of Rheumatology and Immunology at NanjingUniversity Medical School's renowned Drum Tower Hospital Dr. Lingyun Sun andcolleagues report on 16 patients with severe SLE that did not respond tostandard treatments. All 16 patients received stem cell transplants. Tenpatients completed at least 6 months of follow-up and 2 patients were followedfor more than 2 years. There was no treatment-related mortality or otheradverse event during or after UC-MSCT, according to the article.
In comments to Reuters on the report, Dr. Sun said, "The disease activityamong patients was significantly improved during the first 3 months offollow-up." After nearly two years, "most patients show clinical remissionwith no adverse events detected to date or treatment-related mortality."
Dr. Sun added, "We have been working with multiple centers in China forour further studies with more patients being recruited and longer periods forfollow-up, which will be compared to the standard treatment to determine thelong-term efficacy and safety of this novel approach to treat refractorylupus."
The umbilical cord-derived mesenchymal stem cells used in the study wereprocessed by Beike Biotech's scientists (http://www.beikebiotech.com ) at thecompany's new state-of-the-art Jiangsu Stem Cell Regenerative MedicineFacility in Taizhou, China. The facility was recently awarded ISO9001certification for its stem cell processing.
One of the world's leading stem cell researchers, Dr. Sun has doneextensive work in stem cell therapies yielding numerous papers on his clinicaltrial results in the academic journals Lupus, Stem Cells, and Arthritis &Rheumatism.
Beike Biotechnology Chairman Dr. Sean Hu commented, "This study marks animportant research milestone in the field of stem cell interventions and animportant follow-up to Dr. Sun's previous studies on lupus and stem cells. Weare pleased to see the promise UC-MSCT holds for SLE patients as indicated bythe data and look forward to the publication of follow-up studies."
About Beike Biotechnology Company Limited:
Beike Biotechnology (http://www.beikebiotech.com) is Asia's leadingbiotechnology company focusing on adult stem cell therapies. Beike'sscientists have been focused on the development and commercialization of adultstem cell therapies since 1999. The company currently produces a full line ofstem cell products from umbilical cord, cord blood, and bone marrow stem cells.Beike's stem cell therapies are administered by physicians at leadinghospitals throughout China.
Beike's unique processing technologies prepare the cells for use intreating a variety of serious medical conditions including ataxia, braininjury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiplesclerosis, muscular dystrophy, spinal cord injury and optic nerve pathologies.View the article's abstract athttp://www3.interscience.wiley.com/journal/123421837/abstract
SOURCE Beike Biotechnology Company Limited